ECM
CBAY

Engine Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Engine Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,766,196
Closed -$6.16M – 40
2020
Q2 		$6.16M Sell
1,766,196
-4,474,170
-72% -$12.9M 4.05% 8
2020
Q1 		$11.1M Buy
6,240,366
+1,256,432
+25% +$2.11M 5.78% 7
2019
Q4 		$9.77M Buy
+4,983,934
New +$18.7M 3.81% 9

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Engine Capital Management's CBAY Position: Q3 2020 in Review

Engine Capital Management sold out of Cymabay Therapeutics (CBAY) in Q3 2020, closing a stake of 1,766,196 shares — an estimated $6.16M sold.

Engine Capital Management first reported a position in CBAY in Q4 2019 and held it in 3 quarters. The position peaked at $11.1M in Q1 2020. 120 funds tracked by Wall St. Rank hold CBAY as of Q3 2020.

  • Engine Capital Management reported no remaining Cymabay Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Engine Capital Management sold 1,766,196 Cymabay Therapeutics shares in Q3 2020, an estimated $6.16M.
  • Engine Capital Management first reported a position in Cymabay Therapeutics in Q4 2019 and held it in 3 quarters.
  • Engine Capital Management's Cymabay Therapeutics position peaked at $11.1M in Q1 2020.
  • 120 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2020.

Based on Engine Capital Management's 13F filing for Q3 2020, filed 17 Nov 2020.